This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Province will be Canada’s only one to charge most residents for COVID vaccines during the 2025-26 respiratory virus season ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Coronavirus infections are climbing again, marking another summer wave as children go back to school. But this uptick arrives ...

If you want to understand why Secretary of Health and Human Services Robert F. Kennedy Jr. has halted $500 million in funding ...